ClinicalTrials.gg
CompletedNCT03217734MAPUpdated Jul 9, 2019

MAP Study: Methotrexate and Adalimumab in Psoriasis

A Phase 2/3 interventional study of Adalimumab and Methotrexate in Psoriasis, sponsored by Jeffrey J Crowley MD. Completed at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by Jeffrey J Crowley MD · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2018, 7 years 10 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Apr 2017, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing methotrexate in Psoriasis — 8 open to participants now, 8 under way, none of them phase 3. Methotrexate · Psoriasis.

Enrollment
17th of 31
56 · median 60
Started
2017
with 1 other
Phase 2/3
Only one
of the 31
Registered
18th of 31
by date
Lead sponsor
1 of 31
Jeffrey J Crowley MD

Among the 31 studies testing methotrexate in Psoriasis, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 2/3, and was the 18th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 31 studies testing methotrexate in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing methotrexate in Psoriasis, or all of them as a file.
02

Study summary

Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.

Read the detailed description

Assess the efficacy and safety of ADA compared to ADA/MTX in patients with psoriasis. Many studies of ADA in rheumatoid and psoriatic arthritis have allowed patients on stable doses of MTX to continue on MTX while being treated with ADA. There has been no prospective trial of MTX and ADA concomitantly in psoriasis. Safety of ADA monotherapy vs. combination ADA/MTX will be compared.

Compare anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX. ADA is a fully human monoclonal antibody to TNF-a. More recent advances in detection of ADA antibodies have shown that many patients develop antibodies to ADA while on treatment and some of these antibodies are neutralizing. The presence of anti-ADA antibodies has been correlated with loss of therapeutic response in many disease states.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult (≥ 18yrs) with a diagnosis of moderate to severe plaque psoriasis
  2. Subject must have ≥ 10% body surface area involvement
  3. Subject must have psoriasis area and severity index (PASI) ≥12
  4. Subject has stable psoriasis of at least six months' duration
  5. Male subjects must agree to use a reliable form of during the study and for 180 days after the last dose of study drug. Male subjects must not donate sperm during the study or for 180 days after the last dose of study drug. If female, subject is either not of ( for at least 1 year or surgically sterile) or is of childbearing potential and is using approved method of birth control throughout study and for 180 days after last dose of study drug. Approved methods of birth control include the following:

    1. Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (IUD)
    2. Hormonal contraceptives for 90 days prior to study drug administration
    3. A vasectomized partner
  6. Subject has negative PPD tuberculosis skin test at screening assessment.
  7. Subject must be able and willing to provide written and comply with requirements of this study protocol.

Exclusion criteria

Exclusion Criteria

  1. Diagnosis or presence of guttate, erythrodermic or pustular psoriasis
  2. Any previous exposure to ADA including biosimilar ADA
  3. Moderate to high strength topical (class 4 or greater) or Vitamin D analogues within one week of study entry
  4. Oral systemic therapy (methotrexate, cyclosporine, apremilast, acitretin) within 8 weeks of study entry
  5. Previous intolerance or adverse reaction to MTX
  6. Phototherapy of any type within 4 weeks of study entry (narrowband UVB, psoralen-UVA, 308 nM LASER, commercial tanning units)
  7. IL-12/23 inhibitors (ustekinumab) and any IL-23 inhibitor (guselkumab, tildrakizumab, risankizumab) within 12 weeks of baseline
  8. Other biologic agents within 8 weeks of study entry
  9. History of chronic liver disease, hepatitis, or alcohol abuse
  10. Chronic use of any concomitant medication which has a significant potential for interaction with MTX (e.g. sulfa antibiotics, chronic non-steroidal anti-inflammatory (NSAID) use)
  11. History of tuberculosis, opportunistic infections, or any active infection at screening
  12. Elevated liver enzymes (, ALT, ≥1.5 times normal at screening)
  13. Serum creatinine ≥1.5 (at screening)
  14. Any other laboratory abnormality that would pose a concern for the investigator
  15. Daily alcohol use or consumption of more than four alcoholic drinks (4 ounces) in one 24 hour period
  16. Patients who test positive for or C exposure (previous vaccination to Hepatitis B is allowed)
  17. Cancer within the last five years is exclusionary with the exception of treated cutaneous basal cell carcinoma or squamous cell carcinoma or low-grade cervical intraepithelial neoplasia.
  18. Any patient that is deemed by the investigator to be at a safety risk for the intervention in this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Placebo comparator
    ADA and Placebo

    Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks

    Biological: Adalimumab · Drug: Placebo

  • Active comparator
    ADA and MTX

    Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks

    Biological: Adalimumab · Drug: Methotrexate

Interventions

  • BiologicalAdalimumab

    Subcutaneous Injection

    Also known as: Humira

  • Oral Tablet

    Also known as: MTX

  • DrugPlacebo

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. PASI Change

    Mean percent change in PASI from 16 Weeks to Baseline

    Time frame: 16 weeks

Secondary outcomes

  1. ADA/Anti ADA Antibodies

    Antibodies to Adalimumab at 16 weeks

    Time frame: 16 weeks

07

Study locations

4 sites
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • DermAssociates, PC
    Rockville, Maryland 20850, United States
  • Modern Research Associates, PLLC
    Dallas, Texas 75231, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Dec 2018, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 14, 2017
StartActual
Apr 10, 2017
Primary completionActual
Dec 31, 2018
CompletionActual
Dec 31, 2018
Last update
Jul 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03217734
Lead sponsor
Jeffrey J Crowley MD
Collaborators
AbbVie
Responsible party
Jeffrey J Crowley MD (Jeffrey J Crowley, MD, Prinicipal Investigator, Bakersfield Dermatology & Skin Cancer Medical Group) — Sponsor-investigator
First posted
Jul 14, 2017
Start date
Apr 10, 2017
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Jul 9, 2019

Study contacts

Jeffrey J Crowley, MD
study director · Bakersfield Dermatology and Skin Cancer Medical Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion